Answers are grounded in this paper and cite their sources.
The FDA has issued a requirement for manufacturers of long-acting beta-agonists (LABAs) marketed for asthma to conduct controlled clinical trials to assess the safety of a regimen of LABAs plus inhaled corticosteroids as compared with inhaled corticosteroids alone.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: